Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX23 in advanced solid tumors
NCT04797468Phase 1Withdrawn
- Sponsor
- Henlius
- Start
- Jul 2022
- Primary completion
- Jan 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-human CD19 T cell injection in solid tumor (advanced stage), sponsored by Henlius. Primary endpoints: Number of Participants with Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Planned start Jul 2022; status: withdrawn.
02
Drugs
anti-human CD19 T cell injection
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04797468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04797468.